Hou Jing-Yi, Wu Jia-Rong, Chen Yi-Bing, Xu Dong, Liu Shu, Shang Dan-Dan, Fan Guan-Wei, Cui Yuan-Lu
State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China.
Tianjin Key Laboratory of Transformation of Traditional Chinese Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Pharm Biol. 2022 Dec;60(1):743-754. doi: 10.1080/13880209.2022.2055090.
Acute lung injury (ALI) is a complex, severe inflammation disease with high mortality, and there is no specific and effective treatment for ALI. Qingfei Xiaoyan Wan (QFXYW) has been widely used to treat lung-related diseases for centuries.
This study evaluates the potential effects and elucidates the therapeutic mechanism of QFXYW against LPS induced ALI in mice.
BALB/c Mice in each group were first orally administered medicines (0.9% saline solution for the control group, 0.5 mg/kg Dexamethasone, or 1.3, 2.6, 5.2 g/kg QFXYW), after 4 h, the groups were injected LPS (1.0 mg/kg) to induce ALI, then the same medicines were administered repeatedly. The transcriptomics-based system pharmacological analyses were applied to screen the hub genes, RT-PCR, ELISA, and protein array assay was applied to verify the predicted hub genes and key pathways.
QFXYW significantly decreased the number of leukocytes from (6.34 ± 0.51) × 10/mL to (4.01 ± 0.11) × 10/mL, accompanied by the neutrophil from (1.41 ± 0.19) × 10/mL to (0.77 ± 0.10) × 10/mL in bronchoalveolar lavage fluid (BALF). Based on Degree of node connection (Degree) and BottleNeck (BN), important parameters of network topology, the protein-protein interaction (PPI) network screened hub genes, including IL-6, TNF-α, CCL2, TLR2, CXCL1, and MMP-9. The results of RT-PCR, ELISA, and protein chip assay revealed that QFXYW could effectively inhibit ALI via multiple key targets and the cytokine-cytokine signalling pathway.
This study showed that QFXYW decreased the number of leukocytes and neutrophils by attenuating inflammatory response, which provides an important basis for the use of QFXYW in the treatment of ALI.
急性肺损伤(ALI)是一种复杂的重症炎症性疾病,死亡率高,且尚无针对ALI的特异性有效治疗方法。清肺消炎丸(QFXYW)数百年来一直被广泛用于治疗肺部相关疾病。
本研究评估QFXYW对脂多糖诱导的小鼠ALI的潜在作用,并阐明其治疗机制。
每组BALB/c小鼠首先口服给药(对照组给予0.9%生理盐水溶液,0.5mg/kg地塞米松,或1.3、2.6、5.2g/kg QFXYW),4小时后,各组注射脂多糖(1.0mg/kg)诱导ALI,然后重复给予相同药物。应用基于转录组学的系统药理学分析筛选核心基因,采用RT-PCR、ELISA和蛋白质芯片检测验证预测的核心基因和关键通路。
QFXYW使支气管肺泡灌洗液(BALF)中白细胞数量从(6.34±0.51)×10⁹/mL显著降至(4.01±0.11)×10⁹/mL,同时中性粒细胞从(1.41±0.19)×10⁹/mL降至(0.77±0.10)×10⁹/mL。基于网络拓扑的重要参数节点连接度(Degree)和瓶颈(BN),蛋白质-蛋白质相互作用(PPI)网络筛选出核心基因,包括IL-6、TNF-α、CCL2、TLR2、CXCL1和MMP-9。RT-PCR、ELISA和蛋白质芯片检测结果显示,QFXYW可通过多个关键靶点和细胞因子-细胞因子信号通路有效抑制ALI。
本研究表明,QFXYW通过减轻炎症反应降低白细胞和中性粒细胞数量,为QFXYW用于ALI治疗提供了重要依据。